Sector Irradiation vs. Whole Brain Irradiation After Resection of Singular Brain Metastasis-A Prospective Randomized Monocentric Trial.

brain metastases neuropsychology quality of life radiotherapy stereotactic radiosurgery (SRS)

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2020
Historique:
received: 05 08 2020
accepted: 29 10 2020
entrez: 17 12 2020
pubmed: 18 12 2020
medline: 18 12 2020
Statut: epublish

Résumé

To minimize recurrence following resection of a cerebral metastasis, whole-brain irradiation therapy (WBRT) has been established as the adjuvant standard of care. With prolonged overall survival in cancer patients, deleterious effects of WBRT gain relevance. Sector irradiation (SR) aims to spare uninvolved brain tissue by applying the irradiation to the resection cavity and the tumor bed. 40 were randomized to receive either WBRT (n = 18) or SR (n = 22) following resection of a singular brain metastasis. Local tumor control was satisfactory in both groups. Recurrence was observed earlier in the SR (median 3 months, 1-6) than in the WBRT cohort (median 8 months, 7-9) (HR, 0.63; 95% CI, 0.03-10.62). Seventeen patients experienced a distant intracranial recurrence. Most relapses (n = 15) occurred in the SR cohort, whereas only two patients in the WBRT group had new distant tumor manifestation (HR, 6.59; 95% CI, 1.71-11.49; p = 0.002). Median overall survival (OS) was 15.5 months (range: 1-61) with longer OS in the SR group (16 months, 1-61) than in the WBRT group (13 months, 3-52), without statistical significance (HR, 0.55; 95% CI, 0.69-3.64). Concerning neurocognition, patients in the SR group improved in the follow-up assessments, while this was not observed in the WBRT group. There were positive signals in terms of QOL within the SR group, but no significant differences in the global QLQ and QLQ-C30 summary scores were found. Our results indicate comparable efficacy of SR in terms of local control, with better maintenance of neurocognitive function. Unsurprisingly, more distant intracranial relapses occurred.

Identifiants

pubmed: 33330076
doi: 10.3389/fonc.2020.591884
pmc: PMC7732624
doi:

Banques de données

ClinicalTrials.gov
['NCT01667640']

Types de publication

Journal Article

Langues

eng

Pagination

591884

Informations de copyright

Copyright © 2020 Kerschbaumer, Pinggera, Holzner, Delazer, Bodner, Karner, Dostal, Kvitsaridze, Minasch, Thomé, Seiz-Rosenhagen, Nevinny-Stickel and Freyschlag.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e475-80
pubmed: 21477934
Epilepsy Behav. 2005 Dec;7(4):708-14
pubmed: 16266826
Strahlenther Onkol. 1998 May;174(5):275-8
pubmed: 9614957
J Korean Neurosurg Soc. 2012 Sep;52(3):193-9
pubmed: 23115660
Schweiz Arch Neurol Psychiatr (1985). 1990;141(1):21-30
pubmed: 1690447
Neuro Oncol. 2013 Oct;15(10):1429-37
pubmed: 23956241
J Neurosurg. 2011 Jun;114(6):1585-91
pubmed: 21166567
Neurology. 1989 Jun;39(6):789-96
pubmed: 2725874
Lancet Oncol. 2017 Aug;18(8):1040-1048
pubmed: 28687375
J Pain Symptom Manage. 2010 Feb;39(2):219-29
pubmed: 20152586
J Neurosurg. 2014 Dec;121 Suppl:75-83
pubmed: 25434940
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
N Engl J Med. 1990 Feb 22;322(8):494-500
pubmed: 2405271
Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):187-94
pubmed: 16814946
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Surg Neurol. 2008 Feb;69(2):181-6; discussion 186
pubmed: 18261647
Expert Rev Neurother. 2010 Apr;10(4):563-73
pubmed: 20367208
J Neurooncol. 2005 Oct;75(1):85-99
pubmed: 16215819
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
J Neurooncol. 2004 Mar-Apr;67(1-2):115-21
pubmed: 15072456
JAMA. 1998 Nov 4;280(17):1485-9
pubmed: 9809728
AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):77-87
pubmed: 8381255
Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1
pubmed: 8121569

Auteurs

Johannes Kerschbaumer (J)

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.

Daniel Pinggera (D)

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.

Bernhard Holzner (B)

University Clinic for Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.

Margarete Delazer (M)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Thomas Bodner (T)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Elfriede Karner (E)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Lucie Dostal (L)

Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria.

Irma Kvitsaridze (I)

Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Danijela Minasch (D)

Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Claudius Thomé (C)

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.

Marcel Seiz-Rosenhagen (M)

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.
Department of Neurosurgery, Klinikum Memmingen, Memmingen, Germany.

Meinhard Nevinny-Stickel (M)

Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.

Christian F Freyschlag (CF)

Department of Neurosurgery, Medical University of Innsbruck, Innsbruck, Austria.

Classifications MeSH